Our findings suggest that GPR54 or ERK5 deficient CAR‐T cells exert a favorable killing effect at low effector‐to‐target ratios and lower CAR‐T cell exhaustion, highlighting the promising clinical potential of GPR54 or ERK5 inhibition in CAR‐T cell immunotherapy for human cancer. This evidence concerns the gene MAPK7 and cancer.